173 related articles for article (PubMed ID: 30108227)
21. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
22. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers.
Kang SY; Park CK; Chang DK; Kim JW; Son HJ; Cho YB; Yun SH; Kim HC; Kwon M; Kim KM
Int J Cancer; 2015 Apr; 136(7):1568-78. PubMed ID: 25110875
[TBL] [Abstract][Full Text] [Related]
23. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
24. Recent discoveries in the molecular genetics of Lynch syndrome.
Boland CR
Fam Cancer; 2016 Jul; 15(3):395-403. PubMed ID: 27038793
[TBL] [Abstract][Full Text] [Related]
25. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
26. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.
Haraldsdottir S; Hampel H; Wu C; Weng DY; Shields PG; Frankel WL; Pan X; de la Chapelle A; Goldberg RM; Bekaii-Saab T
Genet Med; 2016 Sep; 18(9):863-8. PubMed ID: 26866578
[TBL] [Abstract][Full Text] [Related]
27. Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome.
Binder H; Hopp L; Schweiger MR; Hoffmann S; Jühling F; Kerick M; Timmermann B; Siebert S; Grimm C; Nersisyan L; Arakelyan A; Herberg M; Buske P; Loeffler-Wirth H; Rosolowski M; Engel C; Przybilla J; Peifer M; Friedrichs N; Moeslein G; Odenthal M; Hussong M; Peters S; Holzapfel S; Nattermann J; Hueneburg R; Schmiegel W; Royer-Pokora B; Aretz S; Kloth M; Kloor M; Buettner R; Galle J; Loeffler M
J Pathol; 2017 Oct; 243(2):242-254. PubMed ID: 28727142
[TBL] [Abstract][Full Text] [Related]
28. Molecular and presymptomatic analysis of a Moroccan Lynch syndrome family revealed a novel frameshift MLH1 germline mutation.
Moufid FZ; Bouguenouch L; El Bouchikhi I; Houssaini MI; Ouldim K
Turk J Gastroenterol; 2018 Nov; 29(6):701-704. PubMed ID: 30289396
[TBL] [Abstract][Full Text] [Related]
29. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
[TBL] [Abstract][Full Text] [Related]
30. Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
Hernandez-Sanchez A; Grossman M; Yeung K; Sei SS; Lipkin S; Kloor M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732349
[TBL] [Abstract][Full Text] [Related]
31. Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals.
Valentin MD; da Silva FC; dos Santos EM; Lisboa BG; de Oliveira LP; Ferreira Fde O; Gomy I; Nakagawa WT; Aguiar Junior S; Redal M; Vaccaro C; Valle AD; Sarroca C; Carraro DM; Rossi BM
Fam Cancer; 2011 Dec; 10(4):641-7. PubMed ID: 21681552
[TBL] [Abstract][Full Text] [Related]
32. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
33. First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.
Ziada-Bouchaar H; Sifi K; Filali T; Hammada T; Satta D; Abadi N
Fam Cancer; 2017 Jan; 16(1):57-66. PubMed ID: 27468915
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
35. Identification of Lynch Syndrome.
Maratt JK; Stoffel E
Gastrointest Endosc Clin N Am; 2022 Jan; 32(1):45-58. PubMed ID: 34798986
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
[TBL] [Abstract][Full Text] [Related]
37. Whole Gene Capture Analysis of 15 CRC Susceptibility Genes in Suspected Lynch Syndrome Patients.
Jansen AM; Geilenkirchen MA; van Wezel T; Jagmohan-Changur SC; Ruano D; van der Klift HM; van den Akker BE; Laros JF; van Galen M; Wagner A; Letteboer TG; Gómez-García EB; Tops CM; Vasen HF; Devilee P; Hes FJ; Morreau H; Wijnen JT
PLoS One; 2016; 11(6):e0157381. PubMed ID: 27300758
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
[TBL] [Abstract][Full Text] [Related]
39. Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary nonpolyposis colorectal cancer.
Montazer Haghighi M; Radpour R; Aghajani K; Zali N; Molaei M; Zali MR
Int J Colorectal Dis; 2009 Aug; 24(8):885-93. PubMed ID: 19479271
[TBL] [Abstract][Full Text] [Related]
40. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
